JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus

HomeETFs

JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus

Johnson & Johnson JNJ set the ball rolling for pharma


Johnson & Johnson JNJ set the ball rolling for pharma and medical system producer third-quarter 2020 earnings on Oct 13, earlier than the opening bell. The world’s greatest healthcare merchandise maker continued its lengthy streak of earnings beat and outpaced income estimates. Additional, the corporate lifted its full-year outlook buoyed by robust demand for its most cancers and Crohn’s illness therapies.

Earnings per share got here in at $2.20, beating the Zacks Consensus Estimate of $1.99 and bettering 3.8% from the year-ago quarter. Revenues grew 2% 12 months over 12 months to $21.1 billion and edged previous the Zacks Consensus Estimate of $20.53 billion. The stronger efficiency was pushed by increased gross sales within the medical system unit, robust demand for a few of its medicine together with Darzalex, Imbruvica and Stelara, and power in client well being merchandise like Tylenol and BandAids (learn: Healthcare ETFs, Shares That Gained Double Digits Final Week).

For 2020, Johnson & Johnson raised its gross sales forecast from $79.9-$81.Four billion to $82-$82.Eight billion and earnings per share steering to $7.95-$8.05 from $7.75-$7.95.

Market affect

Regardless of strong outcomes and an upbeat view, shares of JNJ dropped 2.3% on the Oct 13 buying and selling session. The decline got here as the corporate halted its final-phase of scientific trials for its COVID-19 vaccine candidate on account of an unexplained sickness in one of many 60,000 members. The pause has sparked considerations over the total financial rebound from the coronavirus-led downturn. At the moment, the inventory has a Zacks Rank #3 (Maintain) and a Worth Rating of B. Johnson & Johnson belongs to the underside 28% of the Zacks Business Rank.

ETFs in Focus

Given this, traders ought to intently watch the motion of the inventory and ETFs having a double-digit allocation to this diversified drug maker. Beneath we’ve got highlighted them (see: all of the Healthcare ETFs right here).

iShares U.S. Prescription drugs ETF IHE

This ETF offers publicity to 47 firms that manufacture prescription or over-the-counter medicine or vaccines by monitoring the Dow Jones U.S. Choose 21.6% share. The product has $347.1 million in AUM and expenses 42 bps in charges and bills. Quantity is decrease because it exchanges about 6,000 shares a day. The fund has a Zacks ETF Rank #3 (Maintain) with a Excessive danger outlook (learn: Pharma ETFs to Profit from Lilly’s Coronavirus Antibody Progress).

Well being Care Choose Sector SPDR Fund XLV

Essentially the most-popular healthcare ETF, XLV follows the Well being Care Choose Sector Index. This fund manages almost $23.Three billion in its asset base and trades in heavy quantity of round 7.2 million shares. Expense ratio is available in at 0.13%. In complete, the fund holds 63 securities in its basket, with JNJ taking the highest spot, accounting for 9.7% of the belongings. Pharma accounts for 28.8% share from a sector look, whereas healthcare tools and provides, healthcare suppliers and companies, and biotech have a double-digit publicity every. It has a Zacks ETF Rank #2 (Purchase) with a Medium danger outlook.

iShares Advanced U.S. Progressive Healthcare ETF IEIH

This actively managed ETF employs knowledge science strategies to establish firms with publicity to the progressive healthcare sector. Holding 254 shares in its basket, JNJ is the highest agency with an 8.7% allocation. The product has amassed $25.5 million in its asset base and trades in a meager quantity of 9,000 shares per day on common. It expenses 18 bps in annual charges.

iShares U.S. Healthcare ETF IYH

This fund presents publicity to 122 securities by monitoring the Dow Jones U.S. Well being Care Index. Right here once more, Johnson & Johnson dominates the fund’s returns with 8.8% of the full belongings. By way of industrial publicity, pharma takes the highest spot at 27%, adopted by healthcare tools (25.4%) and biotech (17.8%). The product has amassed almost $2.Three billion in its asset base and expenses 43 bps in annual charges. It trades in a great quantity of round 51,000 shares a day and has a Zacks ETF Rank #2 with a Medium danger outlook (learn: Four Prime ETFs, Shares From Engaging Sectors Pre Q3 Earnings).

Vanguard Well being Care ETF VHT

This ETF tracks the MSCI US Investable Market Well being Care 25/50 Index and holds 431 shares in its basket. Of those, Johnson & Johnson occupies the highest place with an 8.3% allocation. Pharma takes the most important share at 26.3%, whereas healthcare tools and biotech spherical off the highest three spots. VHT can also be one of many common and liquid ETFs with AUM of $11.Four billion and common each day quantity of about 192,000 shares. It expenses 10 bps in annual charges and has a Zacks ETF Rank #2 with a Medium danger outlook.

Need key ETF information delivered straight to your inbox?

Zacks’ free Fund Publication will transient you on high information and evaluation, in addition to top-performing ETFs, every week. Get it free >>

Click on to get this free report

Johnson Johnson (JNJ): Free Inventory Evaluation Report

Well being Care Choose Sector SPDR ETF (XLV): ETF Analysis Experiences

Vanguard Well being Care ETF (VHT): ETF Analysis Experiences

iShares U.S. Healthcare ETF (IYH): ETF Analysis Experiences

iShares U.S. Prescription drugs ETF (IHE): ETF Analysis Experiences

iShares Advanced U.S. Progressive Healthcare ETF (IEIH): ETF Analysis Experiences

To learn this text on Zacks.com click on right here.

Zacks Funding Analysis

Need the newest suggestions from Zacks Funding Analysis? Right this moment, you possibly can obtain 7 Finest Shares for the Subsequent 30 Days. Click on to get this free report

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.



www.nasdaq.com